Atrium Therapeutics, Inc. (RNA) Stock Fundamentals & Financial Metrics

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Price & Volume

Key Metrics at a Glance(as of March 2026)

Scale

Market Cap: $231.78M
TTM Revenue: $0
TTM EBITDA: $0
TTM Net Income: $0
Free Cash Flow: $-33.24M

Profitability & Efficiency

Operating Margin: -88.0%
Net Margin: -84.7%
ROE: N/A
Shares Out.: 17.11M

Valuation

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 1.0x

Balance Sheet

Total Assets: $292.36M
Long-Term Debt: N/A
D/E Ratio: N/A
Equity: $234.10M

Financial Analysis

Revenue & Growth

Atrium Therapeutics, Inc. (RNA) reported trailing twelve months revenue of $0 as of March 2026.

Profitability

Atrium Therapeutics, Inc. generated $0 in TTM net income, with quarterly EBITDA of $-17.13M. The operating margin stands at -88.0%.

Efficiency

The spread between operating margin (-88.0%) and net margin (-84.7%) indicates tight cost control with minimal non-operating drag.

Valuation

RNA trades at a P/S of N/A. The price-to-book ratio of 1.0x suggests the stock trades below its book value.

Cash Flow & Balance Sheet

The company reported negative free cash flow of $-33.24M, indicating cash consumption over the period. The balance sheet shows $292.36M in total assets with no in long-term debt against $234.10M in stockholders equity. Data based on the most recent quarterly reports.